Document is current
Any future updates will be listed below
-
Authors
Serhan, Nadine https://orcid.org/0000-0001-9870-9875
Abdullah, Nasser S. https://orcid.org/0009-0004-6554-5885
Gheziel, Nadine https://orcid.org/0009-0002-8497-770X
Loste, Alexia
Ekren, Rüçhan https://orcid.org/0000-0001-6737-7281
Labit, Elodie https://orcid.org/0000-0002-7659-6248
Gonzalez, Anne-Alicia
Oliva, Giulia https://orcid.org/0009-0006-2026-6027
Tarot, Pauline
Petitfils, Camille https://orcid.org/0000-0002-6884-300X
Payros, Gaëlle
D’Avino, Paolo https://orcid.org/0009-0005-6212-4265
Voisin, Allison
Tinsley, Holly Freya Grace
Gentek, Rebecca
Brosseau, Carole
Bodinier, Marie
Reber, Laurent
Val, Pierre
Akdis, Cezmi A.
Mitamura, Yasutaka
Andiappan, Anand Kumar https://orcid.org/0000-0002-8442-1544
Chan, Jerry Kok Yen
Ginhoux, Florent https://orcid.org/0000-0002-2857-7755
François, Amaury https://orcid.org/0000-0003-1171-7974
Cénac, Nicolas https://orcid.org/0000-0002-1552-7812
Basso, Lilian https://orcid.org/0000-0002-2816-1557
Gaudenzio, Nicolas https://orcid.org/0000-0002-5648-509X
- License Information
-
More Information
Article History
Received: 10 July 2024
Accepted: 16 July 2025
First Online: 27 August 2025
Competing interests
: N. Gaudenzio is (or was) collaborating, consulting or serving as a member of the scientific advisory board for Genoskin (where he is CSO and a shareholder), Escient pharmaceuticals, Aikium, CEVA, MaxiVAX, Boehringer Ingelheim, Novartis, Sanofi, Allegria and argenx. L.R. is (or was) collaborating or consulting for Neovacs, Novartis, CEVA and argenx. The other authors declare no competing interests.
